Three years experience with the prescription of anti-TNF-α inhibitors at Dr Soliman Fakeeh Hospital in Jeddah, Saudi Arabia

International Journal of Rheumatic Diseases

Volumn 12, Issue 1, 2009, Pages 14-19

  Eleishi, Hatem Hamdi ^a,b   Toma, Nader Farid ^a   Chaki, Moustapha Cherif ^a   Nada, Hanan Rabee ^a  

^a DR SOLIMAN FAKEEH HOSPITAL   (Saudi Arabia)

^b NONE   (Saudi Arabia)

Author keywords

Ankylosing spondylitis; Cytokines and mediators; Drug treatment; Health services and health care economics; Rheumatoidarthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INFECTION; INJECTION SITE PAIN; MALE; MENTAL DISEASE; OBESITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SAUDI ARABIA; SIDE EFFECT; SWEAT GLAND DISEASE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DRUG COSTS; FEMALE; HUMANS; INSURANCE BENEFITS; MALE; MIDDLE AGED; PATIENT CARE; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; SAUDI ARABIA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 63849237029     PISSN: 17561841     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01373.x     Document Type: Article

References (15)

1. Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358, 903-11.
2. Choy EH, Panayi GS (2002) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344, 907-16.
3. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, can de Putte LM, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38, 44-8.
4. Van der Heijde D, Calin A, Maxime D, Khan MA, can der Linden S, Bellany N (1999) Selection of instrument in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in ankylosing spondylitis: profess report of the ASAS Working Group. J Rheumatol 21, 2281-5.
5. Anderson JJ, Baron G, can der Heijde D, Felson DT, Dougados M (2001) Ankylosing Spondyltis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44, 1876-86.
6. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck BK, Burgee DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 356, 385-90.
7. Fredriksson T, Pettersson U (1978) Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157, 238-44.
8. Teixeira M, Ferguson A (1979) Uses and limitations of the Crohn's disease activity index. Arq Gastroenterol 16, 67-72.
9. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40, 1202-9.
10. Kamal KM, Madhavan SS, Hornsby JA, Miller LA, Kavookjian J, Scott V (2006) Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 73, 718-24. Epub 2006 August 28.
11. Hay JW (2008) Using pharmacoeconomics to value pharmacotherapy. Clin Pharmacol Ther 84, 197-200.
12. Polinski JM, Maclure M, Marshall B, et al. (2008) Does knowledge of medication prices predict physicians' support for cost effective prescribing policies. Can J Clin Pharmacol 15: E286-94. Epub 2008 July 19.
13. Lybecker KM, Freeman RA (2007) Funding pharmaceutical innovation through direct tax credits. Health Econ Policy Law 2, 267-84.
14. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F (2008) Biologic drugs for rheumatoid arthritis in the Medicare program: A cost-effectiveness analysis. Arthritis Rheum 58, 939-46.
15. Wagner TH, Heisler M, Piette JD (2008) Prescription drug co-payments and cost-related medication underuse. Health Econ Policy Law 3, 51-67.